

Audit Review Table				
Blue Cross and Blue Shield of New Mexico (Org ID: 1825, SubID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2017; Date & Timestamp - 6/12/2018 12:02:54 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care: Prevention and Screening				
Adult BMI Assessment (aba)		79.56%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)				
<i>BMI Percentile</i>		62.53%	R	Reportable
<i>Counseling for Nutrition</i>		54.26%	R	Reportable
<i>Counseling for Physical Activity</i>		47.93%	R	Reportable
Childhood Immunization Status (cis)				
<i>DTaP</i>		78.10%	R	Reportable
<i>IPV</i>		90.02%	R	Reportable
<i>MMR</i>		87.59%	R	Reportable
<i>HiB</i>		87.83%	R	Reportable
<i>Hepatitis B</i>		87.59%	R	Reportable
<i>VZV</i>		86.86%	R	Reportable
<i>Pneumococcal Conjugate</i>		79.56%	R	Reportable
<i>Hepatitis A</i>		84.43%	R	Reportable
<i>Rotavirus</i>		76.40%	R	Reportable
<i>Influenza</i>		48.42%	R	Reportable
<i>Combination #2</i>		73.48%	R	Reportable
<i>Combination #3</i>		69.59%	R	Reportable
<i>Combination #4</i>		68.13%	R	Reportable
<i>Combination #5</i>		62.29%	R	Reportable
<i>Combination #6</i>		40.88%	R	Reportable
<i>Combination #7</i>		61.31%	R	Reportable
<i>Combination #8</i>		40.39%	R	Reportable
<i>Combination #9</i>		37.23%	R	Reportable
<i>Combination #10</i>		36.74%	R	Reportable
Immunizations for Adolescents (ima)				
<i>Meningococcal</i>		66.91%	R	Reportable
<i>Tdap</i>		79.32%	R	Reportable
<i>HPV</i>		27.98%	R	Reportable
<i>Combination #1</i>		65.69%	R	Reportable
<i>Combination #2</i>		25.06%	R	Reportable
Lead Screening in Children (lsc)		39.17%	R	Reportable
Breast Cancer Screening (bcs)		41.93%	R	Reportable
Cervical Cancer Screening (ccs)		50.61%	R	Reportable
Chlamydia Screening in Women (chl)				
<i>16-20 Years</i>		42.73%	R	Reportable
<i>21-24 Years</i>		53.94%	R	Reportable
<i>Total</i>		48.92%	R	Reportable
Effectiveness of Care: Respiratory Conditions				
Appropriate Testing for Children with Pharyngitis (cwp)	Y	69.31%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)		27.81%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y			
<i>Systemic Corticosteroid</i>		37.53%	R	Reportable
<i>Bronchodilator</i>		51.28%	R	Reportable
Medication Management for People with Asthma (ama)	Y			
<i>5-11 Years: Medication Compliance 50%</i>		54.87%	R	Reportable
<i>5-11 Years: Medication Compliance 75%</i>		26.84%	R	Reportable
<i>12-18 Years: Medication Compliance 50%</i>		39.91%	R	Reportable
<i>12-18 Years: Medication Compliance 75%</i>		16.51%	R	Reportable
<i>19-50 Years: Medication Compliance 50%</i>		50.51%	R	Reportable
<i>19-50 Years: Medication Compliance 75%</i>		27.29%	R	Reportable
<i>51-64 Years: Medication Compliance 50%</i>		60.78%	R	Reportable
<i>51-64 Years: Medication Compliance 75%</i>		37.75%	R	Reportable
<i>Total: Medication Compliance 50%</i>		51.52%	R	Reportable
<i>Total: Medication Compliance 75%</i>		27.00%	R	Reportable
Asthma Medication Ratio (amr)	Y			
<i>5-11 Years</i>		77.03%	R	Reportable

Audit Review Table				
Blue Cross and Blue Shield of New Mexico (Org ID: 1825, SubID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2017; Date & Timestamp - 6/12/2018 12:02:54 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
12-18 Years		57.37%	R	Reportable
19-50 Years		41.54%	R	Reportable
51-64 Years		53.43%	R	Reportable
Total		54.53%	R	Reportable
Effectiveness of Care: Cardiovascular Conditions				
Controlling High Blood Pressure (cbp)		45.50%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	55.81%	R	Reportable
Statin Therapy for Patients With Cardiovascular Disease (spc)	Y			
Received Statin Therapy: 21-75 Years (Male)		60.21%	R	Reportable
Statin Adherence 80%: 21-75 Years (Male)		51.74%	R	Reportable
Received Statin Therapy: 40-75 Years (Female)		46.58%	R	Reportable
Statin Adherence 80%: 40-75 Years (Female)		53.92%	R	Reportable
Received Statin Therapy: Total		55.24%	R	Reportable
Statin Adherence 80%: Total		52.41%	R	Reportable
Effectiveness of Care: Diabetes				
Comprehensive Diabetes Care (cdc)				
Hemoglobin A1c (HbA1c) Testing		82.00%	R	Reportable
HbA1c Poor Control (>9.0%)		50.36%	R	Reportable
HbA1c Control (<8.0%)		39.66%	R	Reportable
HbA1c Control (<7.0%)			NR	Not Reported
Eye Exam (Retinal) Performed		51.09%	R	Reportable
Medical Attention for Nephropathy		86.37%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		48.66%	R	Reportable
Statin Therapy for Patients With Diabetes (spd)	Y			
Received Statin Therapy		42.74%	R	Reportable
Statin Adherence 80%		44.67%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions				
Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	61.75%	R	Reportable
Effectiveness of Care: Behavioral Health				
Antidepressant Medication Management (amm)	Y			
Effective Acute Phase Treatment		47.81%	R	Reportable
Effective Continuation Phase Treatment		32.59%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y			
Initiation Phase		47.28%	R	Reportable
Continuation and Maintenance (C&M) Phase		69.47%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y			
30-Day Follow-Up		58.63%	R	Reportable
7-Day Follow-Up		37.41%	R	Reportable
Follow-Up After Emergency Department Visit for Mental Illness (fum)	Y			
30-Day Follow-Up		55.76%	R	Reportable
7-Day Follow-Up		43.07%	R	Reportable
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (fua)	Y			
30-Day Follow-Up: 13-17 Years		5.41%	R	Reportable
7-Day Follow-Up: 13-17 Years		0.00%	R	Reportable
30-Day Follow-Up: 18+ Years		18.46%	R	Reportable
7-Day Follow-Up: 18+ Years		10.30%	R	Reportable
30-Day Follow-Up: Total		18.27%	R	Reportable
7-Day Follow-Up: Total		10.15%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	77.57%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)		39.64%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)		53.85%	NA	Small Denominator
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	50.80%	R	Reportable

Audit Review Table				
Blue Cross and Blue Shield of New Mexico (Org ID: 1825, SubID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2017; Date & Timestamp - 6/12/2018 12:02:54 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y			
1-5 Years		16.67%	NA	Small Denominator
6-11 Years		25.37%	R	Reportable
12-17 Years		29.19%	R	Reportable
Total		27.51%	R	Reportable
Effectiveness of Care: Medication Management				
Annual Monitoring for Patients on Persistent Medications (mpm)	Y			
ACE Inhibitors or ARBs		81.80%	R	Reportable
Diuretics		84.18%	R	Reportable
Total		82.66%	R	Reportable
Effectiveness of Care: Overuse/Appropriateness				
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)		1.84%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	89.80%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	32.87%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)		70.51%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y			
1-5 Years		0.00%	NA	Small Denominator
6-11 Years		0.99%	R	Reportable
12-17 Years		4.17%	R	Reportable
Total		2.82%	R	Reportable
Use of Opioids at High Dosage (uod)	Y	39.52	R	Reportable
Use of Opioids From Multiple Providers (uop)	Y			
Multiple Prescribers		229.35	R	Reportable
Multiple Pharmacies		78.25	R	Reportable
Multiple Prescribers and Multiple Pharmacies		42.55	R	Reportable
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health Services (aap)				
20-44 Years		70.44%	R	Reportable
45-64 Years		79.66%	R	Reportable
65+ Years		89.59%	R	Reportable
Total		74.67%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)				
12-24 Months		94.93%	R	Reportable
25 Months - 6 Years		84.39%	R	Reportable
7-11 Years		86.38%	R	Reportable
12-19 Years		85.24%	R	Reportable
Annual Dental Visit (adv)	Y			
2-3 Years		55.57%	R	Reportable
4-6 Years		70.47%	R	Reportable
7-10 Years		72.41%	R	Reportable
11-14 Years		68.03%	R	Reportable
15-18 Years		58.96%	R	Reportable
19-20 Years		39.22%	R	Reportable
Total		64.38%	R	Reportable
Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)	Y			
Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years		45.65%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years		19.57%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years		66.67%	NA	Small Denominator
Opioid abuse or dependence: Engagement of AOD Treatment: 13-17 Years		0.00%	NA	Small Denominator
Other drug abuse or dependence: Initiation of AOD Treatment: 13-17 Years		53.54%	R	Reportable

Audit Review Table				
Blue Cross and Blue Shield of New Mexico (Org ID: 1825, SubID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2017; Date & Timestamp - 6/12/2018 12:02:54 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Other drug abuse or dependence: Engagement of AOD Treatment: 13-17 Years		17.32%	R	Reportable
Total: Initiation of AOD Treatment: 13-17 Years		49.69%	R	Reportable
Total: Engagement of AOD Treatment: 13-17 Years		16.35%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: 18+ Years		39.22%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 18+ Years		13.42%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 18+ Years		46.59%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: 18+ Years		25.50%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: 18+ Years		39.25%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: 18+ Years		11.29%	R	Reportable
Total: Initiation of AOD Treatment: 18+ Years		40.04%	R	Reportable
Total: Engagement of AOD Treatment: 18+ Years		15.51%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: Total		39.31%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: Total		13.51%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: Total		46.66%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: Total		25.41%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: Total		39.95%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: Total		11.59%	R	Reportable
Total: Initiation of AOD Treatment: Total		40.27%	R	Reportable
Total: Engagement of AOD Treatment: Total		15.53%	R	Reportable
Prenatal and Postpartum Care (ppc)				
Timeliness of Prenatal Care		78.59%	R	Reportable
Postpartum Care		61.07%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)				
1-5 Years	Y	33.33%	NA	Small Denominator
6-11 Years		52.46%	R	Reportable
12-17 Years		67.82%	R	Reportable
Total		60.93%	R	Reportable
Utilization				
Well-Child Visits in the First 15 Months of Life (w15)				
0 Visits		4.51%	R	Reportable
1 Visit		3.09%	R	Reportable
2 Visits		3.52%	R	Reportable
3 Visits		4.77%	R	Reportable
4 Visits		9.15%	R	Reportable
5 Visits		15.99%	R	Reportable
6+ Visits		58.97%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)		57.23%	R	Reportable
Adolescent Well-Care Visits (awc)		33.35%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable
Ambulatory Care: Dual Eligibles (ambb)			NR	Not Reported
Ambulatory Care: Disabled (ambc)			NR	Not Reported
Ambulatory Care: Other (ambd)			NR	Not Reported
Inpatient Utilization—General Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient Utilization—General Hospital/Acute Care: Dual Eligibles (ipub)			NR	Not Reported
Inpatient Utilization—General Hospital/Acute Care: Disabled (ipuc)			NR	Not Reported
Inpatient Utilization—General Hospital/Acute Care: Other (ipud)			NR	Not Reported
Identification of Alcohol and Other Drug Services: Total (iada)	Y		R	Reportable

Audit Review Table

Blue Cross and Blue Shield of New Mexico (Org ID: 1825, SubID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)

Measurement Year - 2017; Date & Timestamp - 6/12/2018 12:02:54 PM

The Auditor lock has been applied to this submission.

Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y		NR	Not Reported
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y		NR	Not Reported
Identification of Alcohol and Other Drug Services: Other (iadd)	Y		NR	Not Reported
Mental Health Utilization: Total (mpta)	Y		R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y		NR	Not Reported
Mental Health Utilization: Disabled (mptc)	Y		NR	Not Reported
Mental Health Utilization: Other (mptd)	Y		NR	Not Reported
Antibiotic Utilization: Total (abxa)	Y		R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y		NR	Not Reported
Antibiotic Utilization: Disabled (abxc)	Y		NR	Not Reported
Antibiotic Utilization: Other (abxd)	Y		NR	Not Reported
Standardized Healthcare-Associated Infection Ratio (hai)			R	Reportable
Risk Adjusted Utilization				
Plan All-Cause Readmissions (pcr)			R	Reportable
Health Plan Descriptive Information				
Board Certification (bcr)			R	Reportable
Enrollment by Product Line: Total (enpa)			R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)			NR	Not Reported
Enrollment by Product Line: Disabled (enpc)			NR	Not Reported
Enrollment by Product Line: Other (enpd)			NR	Not Reported
Enrollment by State (ebs)			R	Reportable
Language Diversity of Membership (ldm)			NR	Not Reported
Race/Ethnicity Diversity of Membership (rdm)			NR	Not Reported
Total Membership (tlm)			R	Reportable
Measures Collected using Electronic Clinical Data Systems				
Depression Screening and Follow-Up for Adolescents and Adults (dsf)				
<i>Depression Screening: Total Total</i>			NR	Not Reported
<i>Follow-up on Positive Screen: Total Total</i>			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				
<i>Utilization of PHQ-9: Total Total</i>			NR	Not Reported
Depression and Remission or Response for Adolescents and Adults (drr)				
<i>Follow-up PHQ-9: Total Total</i>			NR	Not Reported
<i>Depression Remission: Total Total</i>			NR	Not Reported
<i>Depression Response: Total Total</i>			NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (asf)				
<i>Alcohol Use Screening: Total Total</i>			NR	Not Reported
<i>Counseling or Other Follow-up Postive Screen: Total Total</i>			NR	Not Reported